🚀 VC round data is live in beta, check it out!
Heron Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Heron Therapeutics and similar public comparables like Editas Medicine, Cereno Scientific, Mycenax Biotech, Elicio Therapeutics and more.
Heron Therapeutics Overview
About Heron Therapeutics
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Founded
1983
HQ
Employees
122
Website
Sectors
Financials (LTM)
EV
$300M
Heron Therapeutics Financials
Heron Therapeutics reported last 12-month revenue of $159M and EBITDA of $15M.
In the same LTM period, Heron Therapeutics generated $118M in gross profit, $15M in EBITDA, and had net loss of ($17M).
Revenue (LTM)
Heron Therapeutics P&L
In the most recent fiscal year, Heron Therapeutics reported revenue of $155M and EBITDA of $15M.
Heron Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $159M | XXX | $155M | XXX | XXX | XXX |
| Gross Profit | $118M | XXX | $114M | XXX | XXX | XXX |
| Gross Margin | 74% | XXX | 73% | XXX | XXX | XXX |
| EBITDA | $15M | XXX | $15M | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | 10% | XXX | XXX | XXX |
| EBIT Margin | (0%) | XXX | (1%) | XXX | XXX | XXX |
| Net Profit | ($17M) | XXX | ($20M) | XXX | XXX | XXX |
| Net Margin | (10%) | XXX | (13%) | XXX | XXX | XXX |
| Net Debt | — | — | $112M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Heron Therapeutics Stock Performance
Heron Therapeutics has current market cap of $207M, and enterprise value of $300M.
Market Cap Evolution
Heron Therapeutics' stock price is $1.13.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $300M | $207M | 0.0% | XXX | XXX | XXX | $-0.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHeron Therapeutics Valuation Multiples
Heron Therapeutics trades at 1.9x EV/Revenue multiple, and 20.3x EV/EBITDA.
EV / Revenue (LTM)
Heron Therapeutics Financial Valuation Multiples
As of March 21, 2026, Heron Therapeutics has market cap of $207M and EV of $300M.
Equity research analysts estimate Heron Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Heron Therapeutics has a P/E ratio of (12.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $207M | XXX | $207M | XXX | XXX | XXX |
| EV (current) | $300M | XXX | $300M | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | 20.3x | XXX | 20.3x | XXX | XXX | XXX |
| EV/EBIT | (1127.8x) | XXX | (167.6x) | XXX | XXX | XXX |
| EV/Gross Profit | 2.5x | XXX | 2.6x | XXX | XXX | XXX |
| P/E | (12.5x) | XXX | (10.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (10.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Heron Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Heron Therapeutics Margins & Growth Rates
Heron Therapeutics' revenue in the last 12 month grew by 15%.
Heron Therapeutics' revenue per employee in the last FY averaged $1.3M.
Heron Therapeutics' rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Heron Therapeutics' rule of X is 46% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Heron Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 64% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 24% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 46% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 32% | XXX | 32% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 34% | XXX | 35% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 75% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Heron Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Editas Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Cereno Scientific | XXX | XXX | XXX | XXX | XXX | XXX |
| Mycenax Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Elicio Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Searle Co. | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Heron Therapeutics M&A Activity
Heron Therapeutics acquired XXX companies to date.
Last acquisition by Heron Therapeutics was on XXXXXXXX, XXXXX. Heron Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Heron Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHeron Therapeutics Investment Activity
Heron Therapeutics invested in XXX companies to date.
Heron Therapeutics made its latest investment on XXXXXXXX, XXXXX. Heron Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Heron Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Heron Therapeutics
| When was Heron Therapeutics founded? | Heron Therapeutics was founded in 1983. |
| Where is Heron Therapeutics headquartered? | Heron Therapeutics is headquartered in United States. |
| How many employees does Heron Therapeutics have? | As of today, Heron Therapeutics has over 122 employees. |
| Who is the CEO of Heron Therapeutics? | Heron Therapeutics' CEO is Craig A. Collard. |
| Is Heron Therapeutics publicly listed? | Yes, Heron Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Heron Therapeutics? | Heron Therapeutics trades under HRTX ticker. |
| When did Heron Therapeutics go public? | Heron Therapeutics went public in 1987. |
| Who are competitors of Heron Therapeutics? | Heron Therapeutics main competitors are Editas Medicine, Cereno Scientific, Mycenax Biotech, Elicio Therapeutics. |
| What is the current market cap of Heron Therapeutics? | Heron Therapeutics' current market cap is $207M. |
| What is the current revenue of Heron Therapeutics? | Heron Therapeutics' last 12 months revenue is $159M. |
| What is the current revenue growth of Heron Therapeutics? | Heron Therapeutics revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Heron Therapeutics? | Current revenue multiple of Heron Therapeutics is 1.9x. |
| Is Heron Therapeutics profitable? | Yes, Heron Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Heron Therapeutics? | Heron Therapeutics' last 12 months EBITDA is $15M. |
| What is Heron Therapeutics' EBITDA margin? | Heron Therapeutics' last 12 months EBITDA margin is 9%. |
| What is the current EV/EBITDA multiple of Heron Therapeutics? | Current EBITDA multiple of Heron Therapeutics is 20.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.